

FINAL RESUME ON THE RESEARCH UNIT:
Institute of Metabolic and Cardiovascular
Diseases (I2MC)

UNDER THE SUPERVISION OF THE
FOLLOWING INSTITUTIONS AND
RESEARCH BODIES:

Université Toulouse 3 - Paul Sabatier – UPS
Institut National de la Santé et de la Recherche
Médicale – Inserm

EVALUATION CAMPAIGN 2019-2020
GROUP A



In the name of Hcéres¹:

Nelly Dupin, acting
President

In the name of the experts committee²:

Luc Bertrand, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Tables in this document were filled with data submitted by the supervising body on behalf the unit.

UNIT PRESENTATION

Unit name :	Institute of Metabolic and Cardiovascular Diseases
Unit acronym :	I2MC
Current label and N° :	UMR 1048
ID RNSR :	201119371M
Application type :	Restructuration
Head of the unit (2019-2020):	Mr Angelo PARINI
Project leader (2021-2025):	Mr Dominique LANGIN
Number of teams and/or themes:	11

EXPERTS COMMITTEE MEMBERS

Chair:	Mr LUC BERTRAND, Université Catholique de Louvain/FNRS, Belgique
Experts:	Ms Elisabetta CERBAI, Università degli Studi di Firenze, Italy
	Mr Aristidis CHARONIS, Biomedical Research Foundation of the Academy of Athens, Greece
	Mr Thierry COUFFINHAL, Université de Bordeaux
	Ms Hélène DUEZ, Inserm/Institut Pasteur de Lille (representative of Inserm CSS3)
	Mr Hervé DURAND, Inserm, Paris (supporting personnel)
	Mr Christophe ERNEUX, Université Libre de Bruxelles, Belgique
	Mr Jacques GROBER, Agrosup Dijon (representative of CNU)
	Mr Bruno GUIGAS, Leiden University, Netherlands
	Ms Florence PINET, Inserm - Institut Pasteur de Lille

HCÉRES REPRESENTATIVE

Mr Claude DELCAYRE

REPRESENTATIVES OF SUPERVISING INSTITUTIONS AND BODIES

Mr Valentin ALEXIS, Université Toulouse 3
Mr Matthieu ARLAT, Université Toulouse 3

Ms Armelle Barelli, Inserm

Mr Raymond Bazin, Inserm

Mr Didier CARRIE, Faculté de médecine Purpan (partenaire)

Mr Elie SERRANO, Faculté de médecine Rangueil (partenaire)

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The Institute of Cardiovascular and Metabolic Diseases (I2MC) was created in 2011 and results from the assembly of preexisting Inserm research units working on metabolic and cardiovascular diseases nearby the corresponding Clinical Departments at Toulouse University Hospitals. It was renewed in 2016 for a 5-year mandate by Inserm and Paul Sabatier University. I2MC is located on the Rangueil Campus in three connected buildings.

The I2MC unit is composed of multi-faceted coordinated research teams, with 14 different teams for the former 5-year period, reorganized in 11 new teams for the future period.

Four research teams joined I2MC since 2011. They particularly strengthened intracellular signaling, lipid metabolism and signaling, angiogenesis, stem/progenitor cell biology, post-transcriptional regulation of gene expression and mitochondrial dynamic/function. Of note, the two emerging teams (previously number 13 and 14) postulate as full teams in the next mandate.

Research teams have the chance to have access to 7 different core facilities located in the unit and that helps them in their research. These include Lipidomics, Imaging, Bioinformatics, Functional Biochemistry, Cytometry, Histology, Genomics & Transcriptomics.

MANAGEMENT TEAM

For the previous period, the governance was represented by the director Mr A. PARINI, 4 deputy directors Mr D. LANGIN, Ms A. NÈGRE-SALVAYRE, Mr P. GOURDY and Mr F. LEZOUALC'H and the administrative director Ms K. MOREIRA.

For the next mandate, the proposed governance body includes the director Mr D. LANGIN, deputy director (to be elected by councils) and the administrative director Ms K. MOREIRA.

HCÉRES NOMENCLATURE

SVE5 Physiology, Physiopathology, Cardiology, Pharmacology, Endocrinology, Cancer, Medical Technologies

SVE2 Cell Biology, Imaging, Molecular Biology, Biochemistry, Genomics, Systems Biology, Development, Structural Biology

THEMATICS

The research developed by I2MC is related to metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (including thrombosis, atherosclerosis, cardiac and renal failure).

UNIT WORKFORCE

I2MC		
Active staff	Number 06/30/2019	Number 01/01/2021
Full professors and similar positions	30	25
Assistant professors and similar positions	35	32
Full time research directors (Directeurs de recherche) and similar positions	18	17
Full time research associates (Chargés de recherche) and similar positions	29	27
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	0	0
High school teachers	0	0

Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	65	57
Permanent staff	177	158
Non-permanent professors and associate professors, including emeritus	11	
Non-permanent full time scientists, including emeritus, post-docs (except PhD students)	16	
PhD Students	50	
Non-permanent supporting personnel	20	
Non-permanent staff	97	
Total	274	158

GLOBAL ASSESSMENT OF THE UNIT

Overall, the quality of I2MC unit is excellent with a significant number of outstanding teams.

The unit is currently composed of teams with internationally recognized expertise in their respective fields and brilliant scientists with international reputation. Using a multi-disciplinary approach, the research performed by the unit is at the bridge between basic and clinical research in the domain of important metabolic diseases such as diabetes and cardiovascular diseases. A significant series of basic and clinical research led to outstanding findings published in international top journals. More importantly, these discoveries bring new clues in the understanding of the laws of nature and propose novel possible therapeutic approaches for important diseases.

During the last mandate, they obtained many external grants with 2 new contracts obtained in 2019, an ERC synergy grant and a H2020 program as coordinators.

The quality of the research would not be possible without the overall organisation of the unit with a strong and committed management that possesses a clear view of the road to follow. Several measures were previously initiated to further improve the efficiency of the unit. Amongst others, the creation of several scientific core facilities brought important expertises necessary to the researchers to reach their goals. Training of master and PhD students as well as of post-docs leads to overall excellent scientific production by training.

The visiting committee was positively impressed by the numerous qualities of the future director of the unit, to lead and create synergisms between the different team members. We are confident that he is fully qualified to reach these goals to implement a strategy/policy in the unit and to further promote it to the top scientific level.

In order to stay in the top level laboratories in their competitive field, the unit should improve its international visibility and attractivity to high level scientists and students by all means.

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
International evaluation and accreditation



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)